Current status of amorphous formulation and other special dosage forms as formulations for early clinical phases

Journal of Pharmaceutical Sciences

Volumn 98, Issue 9, 2009, Pages 2875-2885

  Kawakami, Kohsaku ^a  

^a NATIONAL INSTITUTE FOR MATERIALS SCIENCE   (Japan)

Author keywords

Amorphous; Crystallization; Developmental strategy; Early clinical phases; Molecular mobility; Special dosage form; Stability

Indexed keywords

CARBAMAZEPINE; CREMOPHOR; CYCLODEXTRIN DERIVATIVE; ER 34122; EXCIPIENT; GELATIN; HYDROXYPROPYLMETHYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE ACETATE SUCCINATE; HYDROXYPROPYLMETHYLCELLULOSE PHTHALATE; IBUPROFEN; INSULIN; ITRACONAZOLE; JNJ 25894934; MACROGOL; MACROGOL 6000; MACROGOL DERIVATIVE; METHYLCELLULOSE; NIFEDIPINE; NITRENDIPINE; OIL; POLOXAMER; POLYSORBATE 80; POVIDONE; PRANLUKAST; RECOMBINANT HUMAN INSULIN; RICINOMACROGOL; TACROLIMUS; TOCOPHEROL DERIVATIVE; TOCOPHERYLPOLYETHYLENEGLYCOL SUCCINATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DRUG DOSAGE FORM; DRUG FORMULATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG STABILITY; HUMAN; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW;

EID: 68949105637     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21816     Document Type: Article

References (64)

1. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3-25. (Pubitemid 27046991)
2. Hann MM, Oprea TI. 2004. Pursuing the leadlikeness concept in pharmaceutical research. Curr Opin Chem Biol 8:255-263.
3. Zhang M-Q, Wilkinson B. 2007. Drug discovery beyond the 'rule-of-five.' Curr Opin Biotechnol 18:478-488.
4. Vistoli G, Pedretti A, Testaet B. 2008. Assessing drug-likeness - What are we missing? Drug Discov Today 13:285-294.
5. Brown D. 2007. Unfinished business: Target-based drug discovery. Drug Discov Today 12:1007-1012. (Pubitemid 350180564)
6. Henck J-O, Byrn S. 2007. Designing a molecular delivery system within a preclinical timeframe. Drug Discov Today 12:189-199. (Pubitemid 46316891)
7. Li P, Zhao L. 2007. Developing early formulations: Practice and perspective. Int J Pharm 341:1-19. (Pubitemid 47088122)
8. Stegemann S, Leveiller F, Franchi D, de Jong H, Lindén H. 2007. When poor solubility becomes an issue: From early stage to proof of concept. Eur J Pharm Sci 31:249-261. (Pubitemid 47079001)
9. Lawrence MJ, Rees GD. 2000. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 45:89-121. (Pubitemid 30943127)
10. Kawakami K, Yoshikawa T. Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof, WO01/076582. Shionogi & Co., Ltd.
11. Kawakami K, Yoshikawa T, Moroto Y, Kanaoka E, Takahashi K, Nishihara Y, Masuda K. 2002. Microemulsion formulation for enhanced absorption of poorly soluble drugs. I. Prescription design. J Control Release 81:65-74. (Pubitemid 34454850)
12. Kawakami K, Yoshikawa T, Hayashi T, Nishihara Y, Masuda K. 2002. Microemulsion formulation for enhanced absorption of poorly soluble drugs. II. In vivo study. J Control Release 81:75-82. (Pubitemid 34454851)
13. Pouton CW, Porter CJH. 2008. Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. Adv Drug Deliv Rev 60:625-637.
14. Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86:1-12. (Pubitemid 127489650)
15. Serajuddin ATM. 1999. Solid dispersion of poorly-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88:1058-1066.
16. Yu L. 2001. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv Drug Deliv Rev 48:27-42. (Pubitemid 32454482)
17. Breitenbach J. 2002. Melt extrusion: From process to drug delivery technology. Eur J Pharm Biopharm 54:107-117. (Pubitemid 34919382)
18. Teagarden DL, Baker DS. 2002. Practical aspects of lyophilization using non-aqueous co-solvent systems. Eur J Pharm Sci 15:115-133.
19. Van Drooge DJ, Hinrichs WLJ, Frijlink HW. 2004. Incorporation of lipophilic drugs in sugar glasses by lyophilization using a mixture of water and tertiary butyl alcohol as solvent. J Pharm Sci 93:713-725.
20. den Brok MWJ, Nuijen B, Lutz C, Opitz HG, Beijnen JH. 2005. Pharmaceutical development of a lyophilised dosage form for the investigational anticancer agent Imexon using dimethyl sulfoxide as solubilising and stabilising agent. J Pharm Sci 94:1101-1114. (Pubitemid 40780776)
21. Bhugra C, Shmeis R, Krill SL, Pikal MJ. 2008. Prediction of onset of crystallization from experimental relaxation times. II. Comparison between predicted and experimental onset times. J Pharm Sci 97:455-472.
22. Bhugra C, Pikal MJ. 2008. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J Pharm Sci 97:1329-1349.
23. Aso Y, Yoshioka S, Kojima S. 2000. Relationship between the crystallization rates of amorphous nifedipine, phenobarbital, and flopropione, and their molecular mobility as measured by their enthalpy relaxation and 1H NMR relaxation times. J Pharm Sci 89:408-416. (Pubitemid 30152440)
24. Zhou D, Zhang GGZ, Law D, Grant DJW, Schmitt EA. 2002. Physical stability of amorphous pharmaceuticals: Importance of configurational thermodynamic quantities and molecular mobility. J Pharm Sci 91:1863-1872. (Pubitemid 34810531)
25. Crowley KJ, Zografi G. 2002. Cryogenic grinding of indomethacin polymorphs and solvates: Assessment of amorphous phase formation and amorphous phase physical stability. J Pharm Sci 91:492-507. (Pubitemid 34139812)
26. Surana R, Pyne A, Suryanarayanan R. 2004. Effect of preparation method on physical properties of amorphous trehalose. Pharm Res 21:1167-1176. (Pubitemid 38960768)
27. Gupta P, Kakumanu VK, Bansal AK. 2004. Stability and solubility of celecoxib-PVP amorphous dispersions: A molecular perspective. Pharm Res 21:1762-1769. (Pubitemid 39390086)
28. Kawakami K, Pikal MJ. 2005. Calorimetric investigation of the structural relaxation of amorphous materials: Evaluating validity of the methodologies. J Pharm Sci 94:948-965. (Pubitemid 40789961)
29. Mao C, Chamarthy SP, Byrn SR, Pinal R. 2006. A calorimetric method to estimate molecular mobility of amorphous solids at relatively low temperatures. Pharm Res 23:2269-2276. (Pubitemid 44511508)
30. Miller DA, McConville JT, Yang W, Williams RO III, McGinity JW. 2007. Hot-melt extrusion for enhanced delivery of drug particles. J Pharm Sci 96:361-376. (Pubitemid 46363567)
31. Newa M, Bhandari KH, Li DX, Kwon TH, Kim JA, Yoo BK, Woo JS, Lyoo WS, Yong CS, Choi HG. 2007. Preparation, characterization and in vivo evaluation of ibuprofen binary solid dispersions with poloxamer 188. Int J Pharm 343:228-237. (Pubitemid 47321028)
32. Chono S, Takeda E, Seki T, Morimoto K. 2008. Enhancement of the dissolution rate and gastrointestinal absorption of pranlukast as a model poorly water-soluble drug by grinding with gelatin. Int J Pharm 347:71-78. (Pubitemid 350180324)
33. Shanbhag A, Rabel S, Nauka E, Casadevall G, Shivanand P, Eichenbaum G, Mansky P. 2008. Method for screening of solid dispersion formulations of low-solubility compounds - Miniaturization and automation of solvent casting and dissolution testing. Int J Pharm 351:209-218. (Pubitemid 351186860)
34. Zerrouk N, Chemtob C, Arnaud P, Toscani S, Dugue J. 2001. In vitro and in vivo evaluation of carbamazepine-PEG 6000 solid dispersions. Int J Pharm 225:49-62.
35. Sugimoto I, Kuchiki A, Nakagawa H, Tohgo K, Kondo S, Iwane I, Takahashi K. 1980. Dissolution and absorption of nifedipine from nifedipine- polyvinylpyrrolidone coprecipitate. Drug Dev Ind Pharm 6:137-160. (Pubitemid 11236605)
36. Kushida I, Ichikawa M, Asakawa N. 2002. Improvement of dissolution and oral absorption of ER-34122, a poorly water-soluble dual 5-lipoxygenase/ cyclooxygenase inhibitor with anti-inflammatory activity by preparing solid dispersion. J Pharm Sci 91:258-266. (Pubitemid 34074484)
37. Yamashita K, Nakate T, Okimoto K, Ohike A, Tokunaga Y, Ibuki R, Higaki K, Kimura T. 2003. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm 267:79-91. (Pubitemid 37352952)
38. Merisko-Liversidge E, Liversidge GG, Cooper ER. 2003. Nanosizing: A formulation approach for poorly-water soluble compounds. Eur J Pharm Sci 18:113-120. (Pubitemid 36184748)
39. Rabinow BE. 2004. Nanosuspensions in drug delivery. Nat Rev Drug Discov 3:785-796.
40. Kesisoglou F, Panmai S, Wu Y. 2007. Nanosizing - Oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 59:631-644. (Pubitemid 47285408)
41. Prausnitz MR, Mitragotri S, Langer R. 2004. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 3:115-124. (Pubitemid 38239773)
42. Patton JS, Byron PR. 2007. Inhaling medicines: Delivering drugs to the body through the lungs. Nat Rev Drug Discov 6:67-74.
43. Owens DR, Grimley J, Kirkpatrick P. 2006. Inhaled human insulin. Nat Rev Drug Discov 5:371-372.
44. Mack GS. 2007. Pfizer dumps Exubera. Nat Biotechnol 25:1331-1332.
45. Kling J. 2008. Inhaled insulin's last gasp? Nat Biotechnol 26:479-480.
46. Tack CJ, Christov V, de Galan BE, Derwahl K-M, Klausmann G, Pelikánová T, Perušičová J, Boss AH, Amin N, Kramer D, Petrucci R, Yu W, the 005 Study Group. 2008. Randomized forced titration to different doses of technosphere insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c patients with type 2 diabetes. J Diabetes Sci Technol 2:47-57.
47. Rave K, Heise T, Heinemann L, Boss AH. 2008. Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: Time action profile and variability in subjects with type 2 diabetes. J Diabetes Sci Technol 2:205-212.
48. Pudipeddi M, Serajuddin ATM. 2005. Trends in solubility of polymorphs. J Pharm Sci 94:929-939.
49. Xie J, Tan JC, Wang C-H. 2008. Biodegradable films developed by electrospray deposition for sustained drug delivery. J Pharm Sci 97:3109-3122.
50. Hilden LR, Morris KR. 2004. Physics of amorphous solids. J Pharm Sci 93:3-12.
51. Crowley KJ, Zografi G. 2003. The effect of low concentrations of molecularly dispersed poly(vinylpyrrolidone) on indomethacin crystallization from the amorphous state. Pharm Res 20:1417-1422. (Pubitemid 37164050)
52. Kawakami K, Miyoshi K, Tamura N, Yamaguchi T, Ida Y. 2006. Crystallization of sucrose glass under ambient conditions: Evaluation of crystallization rate and unusual melting behavior of resultant crystals. J Pharm Sci 95:1354-1363. (Pubitemid 43874449)
53. Kawakami K. 2007. Isothermal crystallization of Imwitor 742 from supercooled liquid state. Pharm Res 24:738-747. (Pubitemid 46411962)
54. Sun Y, Xi H, Ediger MD, Yu L. 2008. Difussionless crystal growth from glass has precursor in equilibrium liquid. J Phys Chem B 112:661-664. (Pubitemid 351212499)
55. Sun Y, Xi H, Chen S, Ediger MD, Yu L. 2008. Crystallization near glass transition: Transition from difussion-controlled to diffusionless crystal growth studied with seven polymorphs. J Phys Chem B 112:5594-5601. (Pubitemid 351704577)
56. 3 precursor particles as detected by time-resolved SAXS. Langmuir 18:8364-8369.
57. Davey RJ, Liu W, Quayle MJ, Tiddy GJT. 2002. In situ monitoring of crystallization processes using synchrotron x-ray diffraction: The search for structural precursors. Cryst Growth Des 2:269-272.
58. Yoshioka S, Aso Y. 2007. Correlations between molecular mobility and chemical stability during storage of amorphous pharmaceuticals. J Pharm Sci 96:960-981. (Pubitemid 46797468)
59. Vasanthavada M, Tong WQ, Joshi Y, Kislalioglu MS. 2004. Phase behavior of amorphous molecular dispersions. I: Determination of the degree and mechanism of solid solubility. Pharm Res 21:1598-1606.
60. Vasanthavada M, Tong WQ, Joshi Y, Kislalioglu MS. 2005. Phase behavior of amorphous molecular dispersions. II: Role of hydrogen bonding in solid solubility and phase separation kinetics. Pharm Res 22:440-448.
61. Kawakami K, Miyoshi K, Ida Y. 2005. Impact of the amount of excess solids on apparent solubility. Pharm Res 22:1537-1543. (Pubitemid 41215895)
62. Marsac PJ, Shamblin SL, Taylor LS. 2006. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm Res 23:2417-2426.
63. Marsac PJ, Li T, Taylor LS. 2009. Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters. Pharm Res 26:139-151.
64. Tao J, Sun Y, Zhang GGZ, Yu L. 2009. Solubility of small-molecule crystals in polymers: D-mannitol in PVP, indomethacin in PVP/VA, and nifedipine in PVP/VA. Pharm Res 26:855-864.